7b01792 Abstract
There is an increasing incidence of
The bioavailability of mebendazole from the solution was found to be 17%
Four different dose forms of mebendazole were administered to human volunteers, and urine was collected and assayed for mebendazole and unconjugated metabolites of mebendazole
Get a printable copy (PDF file) of the complete article (277K), or click on a page image below to browse page by page
The aim of the present study is to explore the possibility to increase the efficacy of mebendazole (MBZ) against secondary cysts of Echinococcus granulosus harbored in mice by augmenting the solubility and bioavailability of the drug
100 mg chewable tablet: 100 mg orally twice a day (morning and evening) for 3 consecutive days
Powder X-ray diffraction (PXRD), differential scanning calorimetry
Fenbendazole and Mebendazole compound belong to the class of organic compounds known as benzimidazolylcarbamic acid esters
Mebendazole also undergoes excessive first-pass effect, resulting in
After oral administration of the same dose, an elimination half-life of 0
Lipid-based self-nanoemulsifying drug delivery system was explored to improve the oral bioavailability and target specificity of mebendazole for treatment of lymphatic worm infestations
5 mg/ml) were administered orally at a dose equivalent to 10 mg/kg of TAL
Mebendazole appears less likely to cause neutropenia
Its poor absorption from the gastrointestinal tract and low bioavailability aroused further research on new formulations of mebendazole to increase the bioavailability and improve the therapeutic efficacy
8 times greater serum levels of mebendazole were obtained when co-administering mebendazole with various
of Drug Metabolism and 3Dept
It is poorly soluble in water resulting in poor absorption from the intestinal tract leading to a decrease in bioavailability